Vector bioprocessing spotlight

Cell & Gene Therapy Insights 2022; 8(3), 451–453

DOI: 10.18609/cgti.2022.068

Published: 1 May 2022
Franz Gerner

Franz Gerner is Chief Technology Officer at Excision BioTherapeutics, a clinical-stage CRISPR company using AAV as transfer vehicle to treat persistent infectious diseases, where he is responsible for CMC and related activities internally and at external contract organizations. Dr Gerner has over 25 years’ experience working in the gene therapy field, in process and analytical development, manufacturing, Quality Control, Quality Assurance and vector development. Prior to joining Excision, he was Vice President of Technical Operations at Axovant/Sio Gene Therapies where he oversaw the activities of CMC activities at contract organizations. Previously, he was one of the early members of Regenxbio, responsible for Process Development, including the establishment and subsequent expansion of in-house capabilities. In addition, he was responsible for new innovative approaches to produce recombinant AAVs. Prior to Regenxbio, he has held increasing positions in the biotech industry. He holds a MS in Chemistry and a PhD in Chemistry with focus on Gene Therapy by the Ludwig-Maximilians-Universität München.